Endocr Relat Cancer

• 

  Publication Venue For

  • Everolimus with or without bevacizumab in advanced pNET: CALGB 80701 (Alliance)..  29:335-344. 2022
  • Cancer clocks in tumourigenesis: the p53 pathway and beyond..  28:R95-R110. 2021
  • ATM deficiency promotes progression of CRPC by enhancing Warburg effect..  26:59-71. 2019
  • Transcriptional profiling reveals distinct classes of parathyroid tumors in PHPT..  25:407-420. 2018
  • OP449 inhibits breast cancer growth without adverse metabolic effects..  24:519-529. 2017
  • Impact of 27-hydroxylase (CYP27A1) and 27-hydroxycholesterol in breast cancer..  24:339-349. 2017
  • Lymphovascular invasion is associated with survival for papillary thyroid cancer..  23:555-562. 2016
  • Evaluation of the pharmacological activities of RAD1901, a selective estrogen receptor degrader..  22:713-724. 2015
  • Biologic and clinical significance of androgen receptor variants in castration resistant prostate cancer..  21:T87-T103. 2014
  • Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer..  20:R83-R99. 2013
  • Obesity and risk of ovarian cancer subtypes: evidence from the Ovarian Cancer Association Consortium..  20:251-262. 2013
  • Arsenic trioxide synergizes with everolimus (Rad001) to induce cytotoxicity of ovarian cancer cells through increased autophagy and apoptosis..  19:711-723. 2012
  • Pathogenesis of prostatic small cell carcinoma involves the inactivation of the P53 pathway..  19:321-331. 2012
  • A pilot genome-wide association study shows genomic variants enriched in the non-tumor cells of patients with well-differentiated neuroendocrine tumors of the ileum..  18:171-180. 2011
  • Molecular signatures of thyroid follicular neoplasia..  17:691-708. 2010